OncoMatch/Clinical Trials/NCT06452602
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
Is NCT06452602 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy and Induction immunochemotherapy followed by concurrent chemoradiotherapy for esophageal cancer.
Treatment: Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy · Induction immunochemotherapy followed by concurrent chemoradiotherapy — This trial is conducted in patients with unresectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 60 patients with unresectable locally advanced esophageal cancer in Tianjin cancer hospital. After 2 cycles of induction immunochemotherapy, 60 patients with ESCC will be divided into 2 groups (CR+PR group and SD+PD group) according to the efficacy of induction therapy. Patients in the CR+PR group will be treated with the same immunochemotherapy regimen plus concurrent radiotherapy (50.4Gy/1.8Gy/28f) . And immunotherapy will maintain for a maximum of 1 year. Patients in the SD+PD group will be treated with concurrent chemoradiotherapy (Radiotherapy: PTV/PGTV:50.4Gy/59.92Gy/28f and another chemotherapy regimen). Immunotherapy will not used during chemoradiotherapy because of immunotherapy resistance. The trial can effectively stratify patients by induction immunochemotherapy, and a more appropriate treatment regimen for patients has the potential to further improve PFS and prolong OS in all patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage II, III, IVA, IVB (8th AJCC)
Clinically staged as II-IVb inoperable locally advanced ESCC(including non-resectable, or with contraindications to or refusal of surgery)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-tumor therapy
Haven't received any previous systemic anti-tumor therapy (including but not limited to systemic chemotherapy, radiotherapy, molecularly targeted drug therapy, immunotherapy, biologic therapy, topical therapy and other investigational therapeutic agents)
Cannot have received: anti-PD-1 therapy
Anti-PD-1 or anti-PD-L1 antibody therapy
Cannot have received: anti-PD-L1 therapy
Anti-PD-1 or anti-PD-L1 antibody therapy
Cannot have received: chemotherapy
chemotherapy
Cannot have received: radiotherapy
radiotherapy
Cannot have received: targeted therapy
targeted therapy
Cannot have received: investigational agent
Participation in a study of an investigational agent or device within 4 weeks before the first dose of study treatment
Cannot have received: anti-tumour vaccine
Received an anti-tumour vaccine or received a live vaccine within 4 weeks before the first dose of study treatment
Lab requirements
Blood counts
ANC ≥1500/μl, platelet count ≥100,000/μl and hemoglobin count ≥9.0 g/dl or ≥5.6 mmol/l
Kidney function
creatinine ≤1.5× ULN or measured or calculated creatinine clearance ≥60 mL/min for those with creatinine levels >1.5× ULN (Calculated from the Cockcroft-Gault formula)
Liver function
total bilirubin ≤1.5× ULN and ALT/AST/AKP levels ≤2.5× ULN and albumin ≥2.8 g/dl
Adequate hematologic function, defined as ANC ≥1500/μl, platelet count ≥100,000/μl and hemoglobin count ≥9.0 g/dl or ≥5.6 mmol/l; Adequate renal function, defined as creatinine ≤1.5× ULN or measured or calculated creatinine clearance ≥60 mL/min for those with creatinine levels >1.5× ULN (Calculated from the Cockcroft-Gault formula); Adequate hepatic function, defined as total bilirubin ≤1.5× ULN and ALT/AST/AKP levels ≤2.5× ULN and albumin ≥2.8 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify